Welcome to our dedicated page for SOPHiA GENETICS SA Ordinary Shares news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on SOPHiA GENETICS SA Ordinary Shares stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is a leader in the field of data-driven medicine, leveraging cutting-edge technology to advance healthcare. Based in Switzerland, the company is renowned for its high medical standards and precision. SOPHiA GENETICS has built the SOPHiA DDM™ Platform, a cloud-based SaaS platform designed to analyze complex genomic and multimodal data, delivering valuable insights for clinical and life sciences research.
Through its innovative platform, SOPHiA GENETICS supports healthcare professionals in over 100 hospitals globally, enabling them to perform faster and more accurate diagnoses using next-generation sequencing (NGS) analytics. The platform also facilitates knowledge sharing within the largest clinical genomics community.
Recently, SOPHiA GENETICS has made significant strides with several notable partnerships:
- Unilabs, a prominent European diagnostic provider, adopted the SOPHiA DDM™ Platform to enhance their HRD-status testing capabilities in solid tumors.
- Syndicate Bio in Nigeria integrated MSK-ACCESS® powered by SOPHiA DDM™, marking the first comprehensive genomic profiling and liquid biopsy availability across Africa.
- Klinikum Klagenfurt in Austria and Instituto Mário Penna in Brazil have also implemented the platform to advance their cancer diagnostics and treatment planning, particularly in blood-related cancers and disorders.
Financially, SOPHiA GENETICS is recognized for its robust operational execution and business momentum, continually reaffirming its guidance. The company is actively collaborating with tech giants like Microsoft and NVIDIA to develop a streamlined whole genome sequencing (WGS) analytical solution, promising rapid and precise insights aiding clinical decision-making.
SOPHiA GENETICS also launched SOPHiA UNITY, a global consortium to accelerate cancer research by harnessing diverse, high-quality data from leading institutions worldwide. The platform’s advanced AI-based technology and proprietary algorithms will support decision-making and expedite oncology research.
For more information, visit SOPHiAGENETICS.com or connect on LinkedIn, X, Facebook, and Instagram.
SOPHiA GENETICS held its Annual General Meeting on June 15, 2022, in St-Sulpice, Switzerland. Shareholders approved all agenda items, with detailed voting results available on the Company's website and to be filed with the SEC. Jean-Michel Cosséry was welcomed as a new board member, bringing over 25 years of industry experience. SOPHiA GENETICS aims to standardize data-driven medicine through its SOPHiA DDM™ Platform, utilized by over 790 institutions worldwide.
SOPHiA GENETICS (Nasdaq: SOPH) has published its inaugural Environmental, Social and Governance (ESG) Impact Summary. This document outlines the Company's policies and initiatives related to innovation, patient data protection, and employee empowerment. According to Co-Founder and CEO Dr. Jurgi Camblong, the report marks the initial steps in their ESG journey, reflecting their commitment to patient care and sustainable healthcare. The ESG Impact Summary is accessible via their website and aims to enhance transparency about the Company’s practices in these vital areas.
SOPHiA GENETICS (Nasdaq: SOPH) announced a collaboration with IDIBAPS and Diagnóstica Longwood to enhance Chronic Lymphocytic Leukemia (CLL) care at the European Hematology Association Congress. This partnership aims to consolidate various guideline recommendations into a single application, improving CLL characterization and research practices in Iberia. Leveraging the SOPHiA DDM™ Platform, hematopathologists can access essential guidelines and identify CLL-specific genes, potentially enhancing patient care for the 100,000+ global annual CLL cases.
SOPHiA GENETICS provided an update on its DEEP-Lung-IV clinical study during the 2022 ASCO Annual Meeting. The study focuses on predicting patient response to immunotherapy using multimodal data analysis. Currently, 19 sites across 7 countries have recruited over 500 patients. Early findings suggest promising potential for identifying predictive signatures for individual patients. Additionally, an agreement with GE Healthcare aims to enhance radiomics analysis workflows. Insights from this study could significantly impact precision medicine for stage IV non-small cell lung cancer.
SOPHiA GENETICS (Nasdaq: SOPH) reported Q1 2022 revenue of $10.9 million, marking a year-over-year growth of 21%. Excluding COVID-19 revenues, the constant currency growth reached 35%. The company maintains its 2022 revenue growth guidance of 30% to 35%, despite a stronger U.S. dollar impacting reported figures. The total genomic profiles analyzed surpassed 1,000,000, and total recurring customers increased to 384. However, the operating loss rose to $25 million, up from $14.1 million in Q1 2021, with a net loss of $25.5 million or $0.40 per share.
SOPHiA GENETICS (Nasdaq: SOPH) announced the nomination of Jean-Michel Cosséry to its Board of Directors. His appointment will be proposed at the Annual General Meeting on June 15, 2022. Cosséry brings over 25 years of experience in the med-tech and pharmaceutical sectors, having held key positions at Novartis, GE Healthcare, and Eli Lilly. CEO Jurgi Camblong highlighted Cosséry's diverse expertise as an asset for accelerating growth in oncology and biopharma. SOPHiA GENETICS aims to establish data-driven medicine as a standard of care globally, serving over 790 institutions.
SOPHiA GENETICS (Nasdaq: SOPH) announced that CFO Ross Muken will participate in the J.P. Morgan 50th Annual Global Technology, Media, and Communications Conference in Boston on May 24, 2022. The company's management will also engage in multiple investor meetings during the event. SOPHiA GENETICS is committed to advancing data-driven medicine through its innovative SOPHiA DDM™ Platform, which is utilized by over 790 healthcare institutions globally. For investor inquiries, contact Jennifer Pottage, Head of Investor Relations.
SOPHiA GENETICS (Nasdaq: SOPH) has announced that its SOPHiA DDM™ Platform has successfully analyzed one million genomic profiles, marking a significant achievement in data-driven medicine. This milestone illustrates the platform's rapid growth, having doubled its analyzed profiles in just under two years. The technology is utilized across over 790 healthcare institutions worldwide, enhancing the accuracy of genomic variant detection and facilitating improved patient care. Collaborations, such as with GE Healthcare, further support advancements in cancer treatment by optimizing therapeutic targeting.
SOPHiA GENETICS (Nasdaq: SOPH) will announce its financial results for Q1 2022 on May 10, 2022, before U.S. market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and future business outlook. The call will be available for live webcasting on the company's Investor Relations website. SOPHiA is committed to data-driven medicine and its SOPHiA DDM™ Platform is utilized by over 790 healthcare institutions worldwide.
SOPHiA GENETICS (Nasdaq: SOPH) reported a 42% year-over-year revenue increase for 2021, totaling $40.5 million. In Q4 2021, revenue reached $10.9 million, up 40% from Q4 2020. The company expanded its customer base, growing total recurring platform customers to 382. Despite strong revenue growth, operating losses increased to $21 million in Q4 and $71.5 million for the full year. The company expects 2022 revenue of $51.5 million to $54 million, reflecting growth of 27% to 33% over 2021. Cash reserves were approximately $265 million as of December 31, 2021.
FAQ
What is the current stock price of SOPHiA GENETICS SA Ordinary Shares (SOPH)?
What is the market cap of SOPHiA GENETICS SA Ordinary Shares (SOPH)?
What does SOPHiA GENETICS do?
What is the SOPHiA DDM™ Platform?
Where is SOPHiA GENETICS based?
Who are some of SOPHiA GENETICS' partners?
What is SOPHiA UNITY?
How does SOPHiA GENETICS support precision medicine?
What recent advancements have SOPHiA GENETICS made?
What is the company's mission?
How does SOPHiA GENETICS ensure data privacy and quality?
How can I learn more about SOPHiA GENETICS?
